JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $97
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $92 to $97.
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $92 to $97.